NEW YORK, NY, May 28, 2014 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced it has expanded its exclusive license agreement for certain biomarker and autoantibody technologies identified by researchers Joshua LaBaer, M.D., Ph.D. and Karen Anderson, M.D., Ph.D. of the Biodesign Institute of Arizona State University. The license provides Provista with access to patents, proprietary technology, materials, processing techniques and protocols necessary for detection of certain autoantibodies and use of certain biomarkers.
Help employers find you! Check out all the jobs and post your resume.
